A new trading day began on Monday, with Cullinan Therapeutics Inc (NASDAQ: CGEM) stock price up 6.82% from the previous day of trading, before settling in for the closing price of $9.68. CGEM’s price has ranged from $5.68 to $13.33 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -45.66% over the past five years. Meanwhile, its annual earnings per share averaged -27.51%. With a float of $39.45 million, this company’s outstanding shares have now reached $59.08 million.
Cullinan Therapeutics Inc (CGEM) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cullinan Therapeutics Inc is 33.22%, while institutional ownership is 77.35%. The most recent insider transaction that took place on Dec 19 ’25, was worth 13,463. In this transaction Chief Scientific Officer of this company sold 1,345 shares at a rate of $10.01, taking the stock ownership to the 132,635 shares. Before that another transaction happened on Dec 18 ’25, when Company’s Chief Legal Officer sold 3,480 for $9.67, making the entire transaction worth $33,652. This insider now owns 135,432 shares in total.
Cullinan Therapeutics Inc (CGEM) Performance Highlights and Predictions
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.73 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -27.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.64% during the next five years compared to -45.66% drop over the previous five years of trading.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Here are Cullinan Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.45.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.68, a number that is poised to hit -0.78 in the next quarter and is forecasted to reach -3.03 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Cullinan Therapeutics Inc (NASDAQ: CGEM) saw its 5-day average volume 1.49 million, a positive change from its year-to-date volume of 0.66 million. As of the previous 9 days, the stock’s Stochastic %D was 14.37%.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 60.92%, which indicates a significant increase from 23.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.93 in the past 14 days, which was higher than the 0.63 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.32, while its 200-day Moving Average is $8.10. Nevertheless, the first resistance level for the watch stands at $10.60 in the near term. At $10.85, the stock is likely to face the second major resistance level. The third major resistance level sits at $11.33. If the price goes on to break the first support level at $9.87, it is likely to go to the next support level at $9.39. Assuming the price breaks the second support level, the third support level stands at $9.14.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
With a market capitalization of 610.85 million, the company has a total of 59,076K Shares Outstanding. Currently, annual sales are 0 K while annual income is -167,380 K. The company’s previous quarter sales were 0 K while its latest quarter income was -50,610 K.
